(Q36762858)

16 August 2017

Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors (English)

1 reference

16 August 2017

5

Kan Yonemori

1 reference

16 August 2017

4

Makoto Kodaira

1 reference

16 August 2017

Kenji Tamura

1

1 reference

16 August 2017

Jun Hashimoto

2

1 reference

16 August 2017

Yuko Tanabe

3

1 reference

16 August 2017

Takashi Seto

6

1 reference

16 August 2017

Fumihiko Hirai

7

1 reference

16 August 2017

Shuji Arita

8

1 reference

16 August 2017

Gouji Toyokawa

9

1 reference

16 August 2017

Lan Chen

10

1 reference

16 August 2017

Hiroshi Yamamoto

11

1 reference

16 August 2017

Toshio Kawata

12

1 reference

16 August 2017

Justin Lindemann

13

1 reference

16 August 2017

Taito Esaki

14

1 reference

16 August 2017

language of work or name

1 reference

1 March 2016

1 reference

Cancer Chemotherapy and Pharmacology

16 August 2017

1 reference

16 August 2017

77

1 reference

16 August 2017

4

1 reference

16 August 2017

787-795

1 reference

Creative Commons Attribution 4.0 International

16 August 2017

start time

1 March 2016

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4819940

Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4819940

Targeting the PI3K-AKT-mTOR signaling network in cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4819940

Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4819940

First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4819940

The Akt/PKB family of protein kinases: a review of small molecule inhibitors and progress towards target validation: a 2009 update

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4819940

Activation of AKT kinases in cancer: implications for therapeutic targeting

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4819940

Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4819940

Chronic inhibition of mammalian target of rapamycin signaling downregulates insulin receptor substrates 1 and 2 and AKT activation: A crossroad between cancer and diabetes?

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4819940

Mechanism and management of AKT inhibitor-induced hyperglycemia

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4819940

Effect of iron deficiency anemia on the levels of hemoglobin A1c in nondiabetic patients

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4819940

HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4819940

10.1007/S00280-016-2987-9

5 September 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference

16 August 2017

PubMed publication ID

26931343

1 reference